Not logged in.png)
Share.png)
SaveShare Save Share Save DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Madurka, Ildiko; Vishnevsky, Alexander; Soriano, Joan B.; Gans, Stephanus J.; Salazar Ore, Danilo Joel; Rendon, Adrian; Ulrik, Charlotte S.; Bhatnagar, Sushma; Krishnamurthy, Srikanth; Mc Harry, Kirsten; Welte, Tobias; Fernandez, Alberto A.; Mehes, Beata; Meiser, Karin; Gatlik, Ewa; Sommer, Ulrike; Junge, Guido; Rezende, Ederlon Share Save Share Save Phenotyping Post TB Obstructive airways disease (TOPD) in IndiaDhar, Raja; Nair, Girija; Jana, Ram; Shah, Arti; Dalal, Alpa; Rajagopala, Srinivas; Sarkar, Malay; Unnithan, Jaymohan; Shah, Arpan; Krishnamurthy, Srikanth; Shahi, Praveen; Patel, Shahid; Chaudhary, Vipin; Patil, Prasad; Karumalai, Priyanka; Shah, Palak; Balasubramaniam, Shobana; Sruthi, J.; Kale, Nisha; Madas, Sapna; Limaye, Sneha; Pawar, Shrikant; Salvi, Sundeep Share Save Share Save Share Save Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trialFrith, Peter A.; Ashmawi, Samiha; Krishnamurthy, Srikanth; Gurgun, Alev; Hristoskova, Sashka; Pilipovic, Virginia; Hamann, Anna Marie; Backer, Arthur; Olsson, Petter; Kostikas, Konstantinos; Diaz, Dina V. Share Save Share Save Share Save Share Save Share Save Share Save Share Save Share Save Share Save Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}